Drugs / Human BCMA targeted CAR-NK cells injection
Human BCMA targeted CAR-NK cells injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06045091 | Jul 2023 → Sep 2025 overdue | plasma cell leukemia, plasma cell myeloma | Hrain Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human BCMA targeted CAR-NK cells injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06045091 ↗ |
| Modality | Cell therapy | “Allogenic genetically modified anti-BCMA CAR transduced NK cells” NCT06045091 ↗ |
| Route | Other | “prior to the first infusion of human BCMA targeted CAR-NK Cells injection” NCT06045091 ↗ |